- Home
- IGT vs ZLAB Comparison
IGT vs ZLAB Comparison
Compare IGT & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGT
- ZLAB
- Stock Information
- Founded
- IGT 2014
- ZLAB 2013
- Country
- IGT United Kingdom
- ZLAB China
- Employees
- IGT N/A
- ZLAB N/A
- Industry
- IGT Services-Misc. Amusement & Recreation
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- IGT Consumer Discretionary
- ZLAB Health Care
- Exchange
- IGT Nasdaq
- ZLAB Nasdaq
- Market Cap
- IGT 3.2B
- ZLAB 3.6B
- IPO Year
- IGT N/A
- ZLAB 2017
- Fundamental
- Price
- IGT $15.69
- ZLAB $35.00
- Analyst Decision
- IGT Strong Buy
- ZLAB Buy
- Analyst Count
- IGT 4
- ZLAB 5
- Target Price
- IGT $23.25
- ZLAB $54.28
- AVG Volume (30 Days)
- IGT 1.8M
- ZLAB 1.0M
- Earning Date
- IGT 07-29-2025
- ZLAB 08-05-2025
- Dividend Yield
- IGT 5.07%
- ZLAB N/A
- EPS Growth
- IGT 44.55
- ZLAB N/A
- EPS
- IGT 1.62
- ZLAB N/A
- Revenue
- IGT $2,434,000,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- IGT $2.11
- ZLAB $44.07
- Revenue Next Year
- IGT $1.40
- ZLAB $49.13
- P/E Ratio
- IGT $9.71
- ZLAB N/A
- Revenue Growth
- IGT 14.38
- ZLAB 43.72
- 52 Week Low
- IGT $13.81
- ZLAB $16.01
- 52 Week High
- IGT $24.13
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- IGT 53.07
- ZLAB 51.28
- Support Level
- IGT $14.80
- ZLAB $34.44
- Resistance Level
- IGT $15.72
- ZLAB $38.18
- Average True Range (ATR)
- IGT 0.36
- ZLAB 1.33
- MACD
- IGT 0.13
- ZLAB -0.44
- Stochastic Oscillator
- IGT 82.79
- ZLAB 17.66
About IGT International Game Technology
International Game Technology PLC is a gaming company that delivers entertaining and responsible gaming experiences for players across all channels. The company operates into single segment namely Gaming & Digital. Geographically, it derives a majority of revenue from the United States. The company also has its presence in Italy, Rest of Europe and Other countries.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.